Page last checked
Selective amylin receptor agonist peptide (investigational) · dosing
Eloralintide dosage chart: the six phase 2 trial regimens
The published trial tested 1–9 mg once weekly for 48 weeks in Phase 2; four fixed-dose groups and two study-set paths ending at 9 mg. It enrolled 263 participants and ran as the 48-week Phase 2 weight-management trial. Eloralintide has no approved dosing label. The registry records 6 active regimens, including distinct starting-dose paths that converge on the same targets. Those are randomized study regimens, not a schedule for personal use.
Source: NCT06230523 — 48-week Phase 2 Eloralintide trial
What matters first
The published trial dosing program
These are the once-weekly dose plans used in the published trial. Where two groups reached the same target from different starting doses, both paths remain visible instead of being collapsed into one row. They describe a randomized protocol under monitoring, not a recommended titration schedule.
| Regimen | Starting dose | Target dose | Path recorded by the registry |
|---|---|---|---|
| 1 | 1 mg weekly | 1 mg weekly | 1 mg |
| 2 | 3 mg weekly | 3 mg weekly | 3 mg |
| 3 | 6 mg weekly | 6 mg weekly | 6 mg |
| 4 | 9 mg weekly | 9 mg weekly | 9 mg |
| 5 | 6 mg weekly | 9 mg weekly | 6 mg → 9 mg |
| 6 | 3 mg weekly | 9 mg weekly | 3 mg → 6 mg → 9 mg |
Source: NCT06230523 — 48-week Phase 2 Eloralintide trial · retrieved 2026-08-29 · the paths above reproduce only the doses the source names. The source does not turn those paths into advice.
| Target-dose group | Mean change at 48 weeks | How the paper reports it |
|---|---|---|
| 1 mg fixed | 9.4% decrease | Target-dose group |
| 3 mg fixed | 12.4% decrease | Target-dose group |
| 6 mg fixed | 17.6% decrease | Target-dose group |
| 9 mg fixed | 20.1% decrease | Target-dose group |
| 6→9 mg | 19.9% decrease | Target-dose group |
| 3→6→9 mg | 16.5% decrease | Target-dose group |
| Placebo | 0.4% decrease | Placebo group |
Source: NCT06230523 — 48-week Phase 2 Eloralintide trial · retrieved 2026-08-29. Each source-named path keeps its own reported figure; groups that ended at the same dose are not merged.
Why there is no Eloralintide dosage chart
A dosage chart is a regulatory artifact before it is an editorial one. It exists when an agency has reviewed a sponsor’s trials, agreed a schedule, and bound the manufacturer to a product of stated identity and potency. Eloralintide has none of that yet.
One trial cannot prove long-term safety or show that the result applies to everyone. The highest dose tested is a study dose, not a target for personal use.
Eloralintide is investigational.
It has no prescribing label or approved dose. The amounts below belong to monitored study groups and are not a schedule for personal use. A recruiting Phase 3 study has no results yet.
Sites that publish a titration chart for a compound at this stage have built it by inference. They take a trial’s target dose and reverse-engineer a plausible ramp toward it. The result looks exactly like a supported schedule and should not be read as one. The table shows only the trial arms that were actually studied.
What this trial record still does not connect
The table above answers one narrow question: what the completed injection study tested. It does not join separate formulations or unfinished trials into a single path. Three boundaries remain attached to the record:
- The recruiting Phase 3 trial has no results or approved launch date
1Reference details
How dosing works in this class
Why the dose escalates instead of starting where it ends
The dose climbs in steps for one reason: how well people tolerate it, not how well it works. The receptors that produce the effect you want are the same ones that slow your stomach down, and your gut reacts hardest when the exposure is new. Hold it steady and the reaction fades. Stepping up gradually is a way of using that — each step is a stretch of time for your body to settle at where it is before the next increase arrives.
The length of each step matters. Shortening it moves the next increase into a period when the body may not have adjusted. Labels and trial plans state the intervals that were tested. A faster ramp was not tested.
Why trial dose groups are not a dosing schedule
A dose-finding trial is an experiment about doses, not a recommendation of one. Its arms exist to spread people across a range so researchers can see the shape of the curve. Some arms are set deliberately low, where too little effect is expected. Others are set high, where people are expected to struggle. Reading the top arm as the target gets the design backwards: the reason for running the whole range was that nobody yet knew which part of it was right.
Trial doses came with screening, monitoring, a set schedule and drug of tested strength and purity. Removing a milligram figure from those conditions removes much of what made it meaningful. The table therefore shows what researchers tested, not a schedule to follow.
Questions about Eloralintide dosing
How was Eloralintide dosed in the trial?
The trial ran 6 once-weekly regimens between 1 mg and 9 mg for 48 weeks. The published paths were 1, 3, 6, 9, 6→9, 3→6→9 mg. These are study regimens, not an approved dosing schedule.
How did the Eloralintide trial increase the dose?
The registry records the dose order for each randomized group: 1, 3, 6, 9, 6→9, 3→6→9 mg. Its study-group descriptions do not state an interval between those steps, so no interval is estimated.
What if side effects make the next step too hard?
The next increase is optional, not automatic. The label allows a longer stay at the current step when needed. A clinician decides what happens after a dose is hard to handle; the schedule alone cannot make that decision.
Was 1 mg of Eloralintide studied?
Yes. One randomized group received 1 mg once weekly for 48 weeks and the group changed by an average of -9.4% by week 48. That proves the dose was studied; it does not make it an approved starting dose or a recommendation.
What is the highest Eloralintide dose on the page?
The highest arm studied was 9 mg once weekly. It is simply the highest amount the trial tested. It is not a maximum dose, because no regulator has set one.
Why do some compounds here have a chart and others do not?
Because a chart is a claim about provenance, not a formatting choice. Where an FDA-approved label specifies a schedule, this site quotes it row by row and cites the label under the table. Where no label exists, the guide shows what trials tested and says plainly that it is not a schedule. For Eloralintide, that is the 48-week phase 2 weight-management trial above.
Where to go next on Eloralintide
- Billings LK et al. Eloralintide for obesity: 48-week Phase 2 trial (PMID 41207310)retrieved 2026-09-07Human trial
- NCT06230523 — 48-week Phase 2 Eloralintide trialretrieved 2026-08-29Human trial